Conduct a phase 2B efficacy study as prescribed in AOI15 with coviliv a proprietary live attenuated virus covid-19 vaccine.
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00048
- Awardee
-
Codagenix Inc. UEI TEMNL437K2F1
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $10,000,000
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · Posted Oct 16, 2017
- Contract value 3% obligated
-
- $10,000,000.00 Current, with exercised options
- $389,449,173.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Farmingdale, NY 11735, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $10,000,000 |
About this award
The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $389.4 million cost-plus-fixed-fee definitive contract to Codagenix Inc. on September 30, 2023, to conduct a Phase 2B efficacy study of Coviliv, a proprietary live attenuated virus COVID-19 vaccine developed using the company's Synthetic Attenuated Virus Engineering platform. Under this contract, which has no set-aside designation, Codagenix will also manufacture SARS-CoV-2 antigen panel assay kits. The contract performance is scheduled for completion by July 31, 2026, with work to be performed in Farmingdale, New York. This award originated from a Biomedical Advanced Research and Development Authority broad agency announcement seeking advanced research and development of medical countermeasures against pandemic and biological threats, including vaccines advancing toward FDA approval or licensure.
This significant investment reflects the federal government's commitment to advancing COVID-19 vaccine candidates through clinical development stages. Codagenix's SAVE platform technology redesigns viral genomes to create weakened viruses capable of generating robust immune responses, offering a differentiated approach to vaccine development. The company has established itself as a key federal partner in pandemic preparedness, having previously received additional Department of Defense and National Institutes of Health funding for dengue and COVID-19 vaccine development programs totaling millions of dollars in research support.
Quick answers
Who was awarded contract 75A50123C00048?
75A50123C00048 was awarded to Codagenix Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2023.
How much is contract 75A50123C00048 worth?
The government has obligated $10,000,000 on 75A50123C00048. Its potential value, with all options, is $389,449,173.
Was contract 75A50123C00048 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award